FFO
BEAM icon

Fortitude Family Office’s Beam Therapeutics BEAM Stock Holding History

Fortitude Family Office’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$357 Buy
15
+11
+275% +$305 ﹤0.01% 1813
2025
Q4 		$111 Sell
4
-1
-20% -$26 ﹤0.01% 1890
2025
Q3 		$121 Sell
5
-26
-84% -$517 ﹤0.01% 1951
2025
Q2 		$527 Buy
+31
New +$540 ﹤0.01% 1784

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Fortitude Family Office's BEAM Position: Q1 2026 in Review

Fortitude Family Office increased its Beam Therapeutics (BEAM) stake by 275% in Q1 2026, buying an estimated $305 and bringing the position to 15 shares worth $357. The position accounts for ﹤0.01% of the portfolio, ranked #1813.

Fortitude Family Office first reported a position in BEAM in Q2 2025 and has held it in 4 quarters since. The position peaked at $527 in Q2 2025. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Fortitude Family Office held 15 shares of Beam Therapeutics worth $357 as of Q1 2026.
  • Fortitude Family Office bought 11 Beam Therapeutics shares in Q1 2026, an estimated $305.
  • Beam Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q1 2026, its #1813 holding.
  • Fortitude Family Office first reported a position in Beam Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Fortitude Family Office's Beam Therapeutics position peaked at $527 in Q2 2025.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Fortitude Family Office's 13F filing for Q1 2026, filed 16 Apr 2026.